Trump strikes deal to lower cost of weight loss drugs

NBC News•Thursday, November 6, 2025 at 5:17:19 PM

Former President Trump has announced a significant agreement with pharmaceutical giants Novo Nordisk and Eli Lilly aimed at reducing the costs of popular GLP-1 weight loss drugs, Wegovy and Zepbound. This move is crucial as it could make these effective treatments more accessible to those struggling with obesity, potentially improving public health outcomes. By lowering prices, more individuals may be able to afford these medications, which can lead to healthier lifestyles and reduced healthcare costs in the long run.

— via World Pulse Now AI Editorial System

Read Original

Was this article worth reading? Share it

Recommended Readings

Dow Jones – Healtha day ago

Health Care Roundup: Market Talk

NeutralHealth

In the latest Market Talks, insights are shared on key players in the Health Care sector, including Novo Nordisk, AstraZeneca, and Hikma Pharmaceuticals. This roundup is important as it provides investors and stakeholders with valuable information on market trends and company performances, helping them make informed decisions.

Read full article

via Dow Jones – Health

The New York Timesa day ago

They Can’t Stand Trump. But His I.V.F. Policy Might Help Them Have Children.

PositiveHealth

Despite their opposition to Trump, many individuals are finding hope in his IVF policy, which could significantly improve access to fertility treatments. This policy aims to support families struggling with infertility, making it easier for them to have children. It's a noteworthy development that highlights how political decisions can have a direct impact on personal lives, especially for those yearning to start a family.

Read full article

via The New York Times

Dow Jones – Health2 days ago

Allies of President Trump and Health Secretary Robert F. Kennedy Jr. are looking to the Make America Healthy Again movement to boost GOP prospects in next year’s midterm elections

PositiveHealth

Allies of President Trump and Health Secretary Robert F. Kennedy Jr. are rallying around the Make America Healthy Again (MAHA) movement, aiming to enhance GOP prospects in the upcoming midterm elections. This collaboration could solidify the MAHA-MAGA alliance, with Kennedy's supporters envisioning him as health secretary for an extended term. This partnership is significant as it highlights a strategic approach to unify health initiatives with political goals, potentially reshaping the Republican agenda.

Read full article

via Dow Jones – Health

NBC News2 days ago

Eli Lilly CEO talks deal to cut medication prices with the Trump administration

PositiveHealth

Eli Lilly's CEO, David Ricks, recently discussed a new agreement with the Trump administration aimed at reducing the prices of their weight loss drug, Zepbound. This deal is significant as it reflects a growing trend towards making essential medications more affordable for consumers, potentially improving access to treatment for many individuals struggling with weight management.

Read full article

via NBC News

NBC News2 days ago

Trump announces deal to lower cost of weight loss drug

PositiveHealth

President Trump has announced a significant deal aimed at lowering the costs of popular weight loss drugs, Wegovy and Zepbound, for Medicare recipients. This move is set to bring relief to many individuals struggling with weight management, as the new pricing will take effect in 2026. The collaboration with pharmaceutical executives highlights a proactive approach to healthcare affordability, which is crucial for millions of Americans looking for effective weight loss solutions.

Read full article

via NBC News

The New York Times2 days ago

Trump Announces Deal to Drop Obesity Drug Prices to as Little as $149 a Month

PositiveHealth

President Trump has made a significant announcement regarding the prices of popular obesity drugs, Wegovy and Zepbound, which will now be available for as low as $149 a month. This deal with pharmaceutical giants Eli Lilly and Novo Nordisk aims to make these medications more accessible for Medicare, Medicaid, and self-paying patients. This move is crucial as it addresses the rising obesity rates in America and provides a more affordable option for those seeking effective weight-loss solutions.

Read full article

via The New York Times

The New York Times2 days ago

What Trump’s New Drug Pricing Deal Means for People With Obesity

PositiveHealth

President Trump's new agreement with drug companies aims to lower drug prices for obesity treatments, which could significantly impact those struggling with weight-related health issues. By introducing a range of prices based on dosage and payment methods, this deal seeks to make essential medications more accessible. This is important because it addresses a growing health crisis and could improve the quality of life for many individuals.

Read full article

via The New York Times

Global News2 days ago

Trump says prices for Ozempic, other weight-loss drugs to drop in U.S.

PositiveHealth

In a significant move for healthcare affordability, Trump announced a deal with Eli Lilly and Novo Nordisk to reduce the prices of popular weight-loss drugs like Ozempic for government health insurance programs and cash payers. This is important because it could make these medications more accessible to those struggling with weight management, potentially improving health outcomes for many Americans.

Read full article

via Global News